Core Viewpoint - The company Kang En Bei has a diverse range of products related to influenza and cold treatment, including antiviral, cough relief, pain relief, anti-infection, and health enhancement products, with ongoing development of additional related products [2] Product Categories - Antiviral products include compound Houttuynia cordata granules, blue honeysuckle granules, and Niuhuang Shangqing capsules [2] - Cough relief products consist of acetylcysteine effervescent tablets, compound fresh bamboo liquid, and various syrups and oral liquids for children [2] - Pain relief and cold products feature ibuprofen granules, compound paracetamol and amantadine capsules, and other related formulations [2] - Anti-infection products include amoxicillin capsules and enteric-coated erythromycin tablets [2] - Health enhancement products comprise vitamins and protein powders [2] Recent Developments - The company has recently received approval for a new traditional Chinese medicine, Qinghouyan lozenges, which can alleviate throat discomfort caused by colds [2] - Other influenza and cold-related products are under development, with the Ivy leaf extract and oral liquid project currently in Phase II clinical trials, aimed at treating cough and phlegm associated with acute tracheobronchitis [2]

Core Viewpoint - The stock price fluctuations of Kang En Bei (600572) are influenced by macroeconomic factors, trends in the pharmaceutical industry, the company's fundamentals, market conditions, and investor sentiment and behavior [1] Company Performance - The company reported normal production and operations, with a projected increase in both revenue and profit by the third quarter of 2025 [1] - The management team is committed to enhancing operational management and advancing various business initiatives [1]

Core Viewpoint - The company, Kang En Bei, is actively expanding its international business, particularly in the field of anti-infection raw materials and traditional Chinese medicine formulations, achieving competitive advantages and making significant progress in international registrations and exports [1] Group 1: International Business Expansion - The company sells products to multiple countries, including Italy and Germany within the EU [1] - The company has developed a competitive advantage in the internationalization of anti-infection raw materials after years of effort [1] - The company is actively expanding its traditional Chinese medicine formulation business internationally [1] Group 2: Product Registration and Export - The company has completed international registrations for several products, including Plurolan tablets/capsules, Chuanlian Ning tablets, Jixuegan cream, and Fengyoujing [1] - Ginkgo biloba extract has obtained the CEP certificate from EDQM, and related products have begun export sales [1] - The company plans to adjust product forms to expand into different international markets [1]

Core Viewpoint - The company emphasizes the importance of expanding its international business, particularly in the field of active pharmaceutical ingredients (APIs) for anti-infection products and traditional Chinese medicine formulations [1] Group 1: International Business Expansion - The company has developed a competitive advantage in the internationalization of APIs in the anti-infection sector after years of effort [1] - The company is actively expanding its international market for traditional Chinese medicine formulations [1] Group 2: Product Registration and Certification - The company has completed international registrations for several products, including Plavix tablets/capsules, Intestinal Tract Ning tablets, Jixuegan ointment, and Fengyoujing [1] - Ginkgo biloba extract has obtained the CEP certificate from EDQM, and related products have begun to be exported [1] Group 3: Market Strategy - The company plans to adjust product forms for different markets and leverage national strategies and policy support, such as the "Belt and Road" initiative, to expand its international market [1]

Core Viewpoint - 康恩贝 (600572.SH) is actively involved in the development and marketing of various medications related to influenza and colds, including antiviral, cough relief, pain relief, anti-infection, and immune-boosting products [1] Product Categories - The company offers antiviral products such as compound Houttuynia cordata granules, blue honeysuckle granules, and Niuhuang Shangqing capsules [1] - Cough relief products include acetylcysteine effervescent tablets, compound fresh bamboo liquid, and various syrups and oral liquids for children [1] - Pain relief and cold medications consist of ibuprofen granules, compound paracetamol and phenylephrine capsules, and other related products [1] - Anti-infection products include amoxicillin capsules and enteric-coated erythromycin tablets [1] - Immune-boosting products feature vitamins and protein powders, along with a newly approved traditional Chinese medicine, Qinghouyan lozenges, for symptomatic relief of throat discomfort caused by colds [1] Research and Development - The company is advancing its research plans for other influenza and cold-related products, with the Ivy leaf extract and oral liquid project currently in Phase II clinical trials, aimed at treating cough and phlegm associated with acute tracheobronchitis [1]

Core Viewpoint - The company emphasizes the importance of expanding its international business, particularly in the field of active pharmaceutical ingredients (APIs) for anti-infection products and traditional Chinese medicine formulations [1] Group 1: International Business Expansion - The company has developed a competitive advantage in the internationalization of APIs in the anti-infection sector after years of effort [1] - The company is actively expanding its international market for traditional Chinese medicine formulations [1] Group 2: Product Registration and Certification - The company has completed international registrations for several products, including Plavix tablets/capsules, Intestinal Tract Ning tablets, Jixuegan ointment, and Fengyoujing [1] - Ginkgo biloba extract has obtained the CEP certificate from EDQM, and related products have begun exporting [1] Group 3: Market Strategy - The company plans to adjust product forms for different markets and leverage national strategies and policy support, such as the Belt and Road Initiative, to expand its international market [1]

Core Viewpoint - The company 康恩贝 (600572.SH) has a diverse range of products related to influenza and cold treatment, including antiviral, cough relief, pain relief, anti-infection, and immunity-enhancing products [1] Product Categories - Antiviral products include compound Houttuynia cordata granules, Lianqiao granules, and Niuhuang Shangqing capsules [1] - Cough relief products consist of acetylcysteine effervescent tablets, compound fresh bamboo liquid, and various syrups and oral liquids for children [1] - Pain relief and cold products feature ibuprofen granules, compound paracetamol and amantadine capsules, and other related formulations [1] - Anti-infection products include amoxicillin capsules and erythromycin enteric-coated tablets [1] - Immunity-enhancing products comprise vitamins and protein powders, along with a newly approved traditional Chinese medicine for throat discomfort relief [1] Research and Development - The company is advancing its research plans for other influenza and cold-related products, with a project involving ivy leaf extract and oral liquid currently in Phase II clinical trials, aimed at treating cough and phlegm associated with acute tracheobronchitis [1]

Core Points - The company announced the completion of the cancellation of certain stock options from the 2022 stock option incentive plan due to the disqualification of some participants [2] - A total of 2.0292 million stock options were canceled, which will not affect the company's share capital [2] Group 1: Stock Option Cancellation - The board of directors and the supervisory board approved the cancellation of stock options for individuals who no longer meet the eligibility criteria due to retirement or resignation [2] - The cancellation was confirmed by the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, and completed on November 12, 2025 [2] Group 2: Shareholder Meeting - The company held its first temporary shareholder meeting on November 13, 2025, with no resolutions being rejected [5] - The meeting was conducted in accordance with the Company Law and the company's articles of association, combining on-site and online voting [6] - Key resolutions included amendments to the company's articles of association and governance rules, all of which were passed with significant support from shareholders [8]

证券日报网讯 11月13日晚间，康恩贝发布公告称，公司于2025年11月6日召开第十一届董事会第十二次 （临时）会议、第十一届监事会第十次（临时）会议审议通过《关于注销2022年股票期权激励计划部分 股票期权的议案》。鉴于截至目前，公司2022年股票期权激励计划（简称"本次激励计划"）的激励对象 中有人员因退休、离职等原因不再具备激励对象资格和行权条件，以及经统计本次激励计划首次授予股 票期权第二个行权期、预留授予股票期权第一个行权期对应考核年度激励对象个人层面绩效考核结果 （不能100%行权的情形），董事会、监事会决定注销上述人员已获授但尚未获准行权的股票期权共计 202.92万份。经中国证券登记结算有限责任公司上海分公司审核确认，上述202.92万份股票期权注销事 宜已于2025年11月12日办理完毕。 （文章来源：证券日报） ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称"公司"）于2025年11月6日召开十 一届董事会第十二次（临时）会议、十一届监事会第十次（临时）会议审议通过 《关于注销2022年股票期权激励计划部分股票期权的议案》。鉴于截至目前，公司 2022年股票期权激励计划（以下简称"本次激励计划"）的激励对象中有人员因退 休、离职等原因不再具备激励对象资格和行权条件，以及经统计本次激励计划首次 授予股票期权第二个行权期、预留授予股票期权第一个行权期对应考核年度激励对 象个人层面绩效考核结果（不能100%行权的情形），董事会、监事会决定注销上述 人员已获授但尚未获准行权的股票期权共计202.92万份。具体内容详见公司于2025 年11月7日披露于上海证券交易所网站www.sse.com.cn和刊登于《中国证券报》 《上海证券报》《证券时报》的公司临2025—059号《公司关于注销2022年股票期 权激励计划部分股票期权的公告》。 经中国证券登记结算有限责任公司上海分公司审核确认，上述202.92万份股 ...